Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 14;42(5):923–934. doi: 10.1007/s10875-022-01231-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Functional immunity following SARS-CoV-2 vaccination in individuals with antibody deficiency. Serum neutralisation capacity was assessed using live virus neutralisation in seropositive individuals sampled 1–2 months post second vaccine dose. A Serum neutralising antibody capacity of seropositive individuals by underlying immunodeficiency. B Comparison of serum neutralising antibody capacity between individuals with prior PCR proven SARS-CoV-2 infection and those who were infection naive. C Comparison of serum neutralising antibody capacity between recipients of the Pfizer and AstraZeneca vaccinations. D Comparison of serum neutralising antibody capacity by age of participants. E Comparison of binding of vaccine-induced IgG antibodies from participants sampled 1–2 months post vaccination to the wild-type (Victoria) SARS-CoV-2 spike protein and the Delta variant of concern within an ELISA detection system. F Comparison of binding of vaccine-induced IgG antibodies from participants sampled 1–2 months post vaccination to the wild-type (Victoria) SARS-CoV-2 spike protein and the Omicron variant of concern within an ELISA detection system